telatinib
Small moleculeexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 25, 2019 (NCT03817411)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
PDGFRB inhibitor
FLT4 inhibitor
KDR inhibitor
- Stem cell growth factor receptorINHIBITOR
KIT inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1- Mol. weight
- 409.83 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2079588 ↗
Also known as
- 4-(((4-((4-chlorphenyl)amino)furo(2,3-d)pyridazin-7-yl)oxy)methyl)-n-methylpyridine-2-carboxamide
- bay 57-9352
- bay-579352
- bay-579352
- bay-57-9352
- bay-57-9352
- telatinib
- telatinib
- telatinib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04798781 | Phase 2 | Jul 28, 2021 | Cedars-Sinai Medical Center, EddingPharm Oncology Co., LTD. |
| NCT03817411 | Phase 2 | Jan 25, 2019 | EddingPharm Oncology Co., LTD., Fudan University, Huazhong University of Science and Technology, Shanghai Easter Hospital |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| EddingPharm Oncology Co., LTD. | For profit | 2 | 1 | 1 | 2019 |
| Cedars-Sinai Medical Center | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Shanghai Easter Hospital | Academic/Hospital | 1 | 0 | 1 | 2019 |
5 organizations
Page 1 / 1